Syncona has a world-leading cell therapy franchise developing products with the potential to treat patients across a range of diseases.
The Syncona team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across innovative areas of cell therapy including: CAR-T, Tumour Infiltrating Lymphocytes, TCRs, T-Regulatory cells, iPSCs and macrophages.
Value of cell therapy portfolio
Number of clinical trials
Financing rounds in previous financial year
Latest cell therapy insights
*Unless stated all financials at 31 December 2021